Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9554-9561

  Delgado, David C ^a   Hank, Jacquelyn A ^b   Kolesar, Jill ^c   Lorentzen, David ^b   Gan, Jacek ^b   Seo, Songwon ^b   Kim, KyungMann ^b   Shusterman, Suzanne ^d   Gillies, Stephen D ^e   Reisfeld, Ralph A ^f   Yang, Richard ^b   Gadbaw, Brian ^b   DeSantes, Kenneth B ^a   London, Wendy B ^d,g   Seeger, Robert C ^h   Maris, John M ⁱ   Sondel, Paul M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e Provenance Biopharmaceuticals Corp   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g CHILDREN S ONCOLOGY GROUP   (United States)

^h CHILDREN S HOSPITAL LOS ANGELES   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR IIA; IMMUNOMODULATING AGENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; MONOCLONAL ANTIBODY HU14.18 INTERLEUKIN 2 FUSION PROTEIN; NATURAL KILLER CELL RECEPTOR; UNCLASSIFIED DRUG;

ALLELE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENOTYPE; HLA SYSTEM; HUMAN; NATURAL KILLER CELL; NEUROBLASTOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; GENOTYPE; HLA ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; INFANT; INTERLEUKIN-2; KILLER CELLS, NATURAL; LIGANDS; NEUROBLASTOMA; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RECEPTORS, KIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649968328     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2211     Document Type: Article

References (23)

1. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9. (Pubitemid 29300166)
2. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172:644-50. (Pubitemid 38020523)
3. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005;105:4878-84. (Pubitemid 40807317)
4. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007;97:539-42. (Pubitemid 47258461)
5. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009;15:7330-4.
6. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
7. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
8. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7. (Pubitemid 46606207)
9. Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet 2008;183:35-40. (Pubitemid 351637610)
10. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
11. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
12. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24:2885-90. (Pubitemid 46630590)
13. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen H, et al. Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-cis retinoic acid for high-risk neuroblastoma: a Children's Oncology Group (COG) phase 3 study. New Engl J Med 2010;363:1324-34.
14. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-94. (Pubitemid 27479718)
15. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-15. (Pubitemid 28110336)
16. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 2004;10:4839-47. (Pubitemid 38955538)
17. Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, et al. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother 2004;53:41-52. (Pubitemid 38161180)
18. Shusterman S, London WB, Gillies SD, Hank JA, Voss S, Seeger RC, et al.. Anti-tumor activity of hu14.18-IL2 in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG) phase II study. J Clin Oncology. Epub 2010 Oct 4.
19. Ronaghi M, Elahi E. Discovery of single nucleotide polymorphisms and mutations by pyrosequencing. Comp Funct Genomics 2002;3:51-6.
20. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994;83:1323-8. (Pubitemid 24062855)
21. Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 1990;31:53-9. (Pubitemid 20045589)
22. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990;50:5234-9. (Pubitemid 20302968)
23. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, et al. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 1991;77:237-44.